English • 中文

Offstream
news

COVID-19 pandemic

Phase III clinical trials for the Novavax COVID-19 vaccine candidate conclude in the U.S. and Mexico, showing an efficacy rating of 90.4%, down from the initial estimate of 96.4% efficacy reported in March. Additionally, the vaccine candidate was also found to be 86.3% effective against the Lineage B.1.1.7 Alpha variant that originated in the United Kingdom.

Novavax says Covid-19 vaccine shows 90.4% overall efficacy in US/Mexico Phase 3 trial

Sources:  CNN International

Changes

  1. Phase III clinical trials for the Novavax COVID-19 vaccine candidate conclude in the U.S. and Mexico, showing an efficacy rating of 90.4%, down from the initial estimate of 96.4% efficacy back in March.
  2. Phase III clinical trials for the Novavax COVID-19 vaccine candidate conclude in the U.S. and Mexico, showing an efficacy rating of 90.4%, down from the initial estimate of 96.4% efficacy reported in March. Additionally, the vaccine candidate was also found to be 86.3% effective against the Lineage B.1.1.7 Alpha variant that originated in the United Kingdom.

Related